(Q46686656)

24 December 2017

title

Systemic lupus erythematosus: clinical manifestations, treatment and economics (English)

1 reference

24 December 2017

systemic lupus erythematosus

main subject

1 reference

Pantelis Panopalis

1

1 reference

24 December 2017

Ann E Clarke

series ordinal

2

1 reference

24 December 2017

publication date

1 October 2006

1 reference

24 December 2017

Expert Review of Pharmacoeconomics & Outcomes Research

published in

1 reference

24 December 2017

volume

6

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

563-575

1 reference

24 December 2017

Incidence of clinically diagnosed systemic lupus erythematosus 1992-1998 using the UK General Practice Research Database.

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Systemic lupus erythematosus, complement deficiency, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

SLE--a disease of clearance deficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Challenges in bringing the bench to bedside in drug development for SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

New treatments for SLE: cell-depleting and anti-cytokine therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Novel therapeutics for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Novel therapeutic agents for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Cost-of-illness studies. Useful for health policy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Cost of illness studies: what is good about them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Economic note: cost of illness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Quality of life and economic evaluation in SLE clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Rheumatoid arthritis: direct and indirect costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.5.563

21 January 2018

Identifiers

DOI

10.1586/14737167.6.5.563

1 reference

24 December 2017

1 reference

24 December 2017